secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001171843-23-006627
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst Q3 2023: ORLADEYO revenue $85.7M (+29.8% yoy); net loss narrows to $36.1M
--------------------------------------------------------------------------------

- Total Q3 2023 revenue $86.7M (+14.4% yoy), driven by ORLADEYO growth of $19.7M.
- Net loss $36.1M ($0.19/share) vs $42.5M ($0.23) in Q3 2022; operating cash use $16.5M (-43.9% yoy).
- Full-year 2023 ORLADEYO revenue guidance reaffirmed at no less than $320M; peak revenue target $1B.
- R&D expenses down 11% yoy to $46.9M due to program discontinuations; SG&A up 37% to $50.7M on ORLADEYO launch.
- Cash and investments $399.2M at Sep 30, 2023; debt interest expense rose on Pharmakon facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184323006627/0001171843-23-006627-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184323006627/f8k_110223.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-006627

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer